Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113085 | 1.00 | CHRM1 (0.45) | CHRM1CHRM2CHRM4NPC1RAB9A | |
| SCHEMBL2114479 | 0.89 | DGAT2 (0.47) | CHRM1CHRM2CHRM4NPC1RAB9A | |
| SCHEMBL10481261 | 0.83 | RAB9A (0.46) | NPC1RAB9AMAOBALDH1A1LMNA | |
| SCHEMBL2610211 | 0.81 | CTSS (0.49) | MAOBALDH1A1LMNACTSSSMN1; SMN2 | |
| SCHEMBL2113907 | 0.81 | CHRM1 (0.54) | CHRM1CHRM2CHRM4NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2114956 | 0.80 | CTSS (0.49) | MAOBALDH1A1LMNACTSSSMN1; SMN2 | |
| SCHEMBL2115308 | 0.79 | CHRM1 (0.52) | CHRM1CHRM2CHRM4NPC1RAB9A | |
| SCHEMBL2610203 | 0.79 | CHRM1 (0.52) | CHRM1CHRM2CHRM4NPC1RAB9A | |
| SCHEMBL2710859 | 0.78 | CTSS (0.67) | ALDH1A1CTSSSMN1; SMN2 | |
| SCHEMBL2112156 | 0.78 | CTSS (0.67) | ALDH1A1CTSSSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227468-B2 | Cathepsin S inhibitor compounds | ELI LILLY AND COMPANY (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012054315-A1 | CATHEPSIN S INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | ELI LILLY AND COMPANY (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095020-A1 | Cathepsin S Inhibitor Compounds | CTSS, CTSZ, CTSV | CHRM1 4241/4885CHRM2 4275/4885CHRM4 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.